Cardiovascular disease biotechnology company Scribe (SCTX.US) plans to price its IPO at $13-15 per share with a goal to raise $100 million.

According to the Wisdom Financial APP, Scribe Therapeutics, a biotechnology company dedicated to developing CRISPR gene therapy for high cholesterol, currently in Phase I clinical stage, announced the terms of its initial public offering (IPO) on Monday. The company plans to issue 7.2 million shares at a price of $13 to $15 per share, raising $100 million. The company plans to list on NASDAQ under the symbol "SCTX".